The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys

Keyphrases

• Muscarinic Receptors 100%
• Receptor Agonist 100%
• Monkey 100%
• Cebus Apella 100%
• Xanomeline 100%
• Antipsychotic Activity 100%
• M4 Receptor 100%
• Extrapyramidal Side Effects 54%
• Apomorphine 36%
• D-amphetamine 36%
• Rodents 18%
• Drug-naïve 18%
• Unrest 18%
• Antipsychotics 9%
• Amphetamine 9%
• Alzheimer's Disease 9%
• High Dose 9%
• Pharmacological Treatment 9%
• Primates 9%
• Dystonia 9%
• Vomiting 9%
• Nonhuman Primate 9%
• Dose-ranging 9%
• Dopamine Receptor 9%
• Psychosis Treatment 9%
• Alzheimer Patients 9%
• Dopamine Antagonism 9%
• Rodent Studies 9%
• Combination Studies 9%
• Alzheime's Disease 9%
• Psychotic-like Experiences 9%
• Antipsychotic Compounds 9%
• Muscarinic Receptor Agonist 9%
• Induced Behavior 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Antipsychotic 100%
• Receptor Agonist 100%
• Sapajus apella 100%
• Xanomeline 100%
• Extrapyramidal Symptoms 54%
• Amphetamine 45%
• Apomorphine 36%
• Alzheimer's Disease 9%
• Dystonia 9%
• Muscarinic Agent 9%
• Dopamine Receptor 9%
• Emetic Agent 9%
• Dopamine 9%
• Psychosis 9%